Asthma Clinical Trial
To characterize the skin route of exposure to the allergen hexamethylene diisocyanate (HDI) in the auto body industry.
BACKGROUND:
Isocyanates account for the highest number of reported cases of occupational asthma in the
United States and developed countries. Prevention, however is limited by inadequate
knowledge of isocyanate routes of exposure, exposure patterns, mechanisms of sensitization
and other causal factors. The Survey of Painters and Repairers of Auto Bodies by Yale
(SPRAY), a five-year cross-sectional epidemiologic survey of painters and repairers of
autobodies at Yale was therefore initiated to address these questions. At the outset of
Spray, it was not known how frequent skin contact among the painters might be. Moreover,
there is new and exciting data from animal studies demonstrating that dermal rather than
respiratory contact may be crucial to immune sensitization leading to asthma. Little is
known, so far, about dermal exposure in autobody shops and its modifiers, especially the
effectiveness of personal protective equipment (PPE) in preventing workers from skin
contamination by isocyanates.
DESIGN NARRATIVE:
The study was ancillary to the SPRAY study and was integrated into it. The overall design
was a cross-sectional investigation of 20 shops with 120 workers. This would allow a better
understanding of the complex basis for asthma risk in these workers, and better
recommendations to autobody shops and workers on protective measures for isocyanate dermal
exposures.
Specific aims included: 1) Qualitatively and quantitatively assessing surface and skin
contamination of HDI; 2) Identifying modifiers that affected surface and skin contamination,
and specifically evaluating the effectiveness of personal protective equipment in protecting
the skin from isocyanate contamination; 3) Exploring the relationships of dermal exposure
with airborne exposure, biomarkers of systemic absorption and skin sensitization, and
asthma-developing risk.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|